$0.97
-0.06 (-5.98%)
Open$1.03
Previous Close$1.03
Day High$1.08
Day Low$0.90
52W High$1.84
52W Low$0.77
Volume—
Avg Volume143.2K
Market Cap17.34M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,264.3% upside
Current
$0.97
$0.97
Target
$32.58
$32.58
$17.80
$32.58 avg
$40.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 361.4K | 2.19M | 1.96M |
| Net Income | -12,660,162 | -647,190 | -493,473 |
| Profit Margin | -3,509.7% | -29.6% | -25.2% |
| EBITDA | -14,208,037 | -712,204 | -583,546 |
| Free Cash Flow | — | -781,686 | -525,232 |
| Rev Growth | — | +18.0% | +10.8% |
| Debt/Equity | 0.14 | 0.28 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |